Denali therapeutics announces positive clinical results and regulatory progress for development programs in amyotrophic lateral sclerosis (als)

South san francisco, calif., oct. 06, 2021 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced positive phase 1 clinical results and regulatory progress for two investigational small molecule therapeutics in development for the treatment of amyotrophic lateral sclerosis (als) at the 2021 annual northeast als (neals) meeting being held virtually, october 6-7.
DNLI Ratings Summary
DNLI Quant Ranking